Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase
Madhav D. Sharma, … , Andrew L. Mellor, David H. Munn
Madhav D. Sharma, … , Andrew L. Mellor, David H. Munn
Published September 4, 2007
Citation Information: J Clin Invest. 2007;117(9):2570-2582. https://doi.org/10.1172/JCI31911.
View: Text | PDF
Research Article Oncology

Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase

  • Text
  • PDF
Abstract

A small population of plasmacytoid DCs (pDCs) in mouse tumor-draining LNs can express the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO). We show that these IDO+ pDCs directly activate resting CD4+CD25+Foxp3+ Tregs for potent suppressor activity. In vivo, Tregs isolated from tumor-draining LNs were constitutively activated and suppressed antigen-specific T cells immediately ex vivo. In vitro, IDO+ pDCs from tumor-draining LNs rapidly activated resting Tregs from non–tumor-bearing hosts without the need for mitogen or exogenous anti-CD3 crosslinking. Treg activation by IDO+ pDCs was MHC restricted, required an intact amino acid–responsive GCN2 pathway in the Tregs, and was prevented by CTLA4 blockade. Tregs activated by IDO markedly upregulated programmed cell death 1 ligand 1 (PD-L1) and PD-L2 expression on target DCs, and the ability of Tregs to suppress target T cell proliferation was abrogated by antibodies against the programmed cell death 1/PD-L (PD-1/PD-L) pathway. In contrast, Tregs activated by anti-CD3 crosslinking did not cause upregulation of PD-Ls, and suppression by these cells was unaffected by blocking the PD-1/PD-L pathway. Tregs isolated from tumor-draining LNs in vivo showed potent PD-1/PD-L–mediated suppression, which was selectively lost when tumors were grown in IDO-deficient hosts. We hypothesize that IDO+ pDCs create a profoundly suppressive microenvironment within tumor-draining LNs via constitutive activation of Tregs.

Authors

Madhav D. Sharma, Babak Baban, Phillip Chandler, De-Yan Hou, Nagendra Singh, Hideo Yagita, Miyuki Azuma, Bruce R. Blazar, Andrew L. Mellor, David H. Munn

×

Figure 2

Activation of Tregs by IDO in vitro.

Options: View larger image (or click on image) Download as PowerPoint
Activation of Tregs by IDO in vitro.
(A) Resting Tregs were cocultured w...
(A) Resting Tregs were cocultured with TDLN pDCs plus OT-I plus feeder cells (all on B6 background, MHC b-haplotype) as described in Methods (IDO-activated Tregs). After 2 days the Tregs were re-sorted and added to readout assays (A1 T cells + CBA DCs, k-haplotype background). Controls Tregs were activated in identical cultures with 1MT added to block IDO activity. Graph shows the mean of 5–8 pooled experiments, using pDCs from B78H1–GM-CSF and B16-OVA tumors; error bars show SD. (B) Tregs were activated as described above or in identical cultures containing 1MT (to block IDO) and anti-CD3 mAb (αCD3) plus IL-2 (IDO-activated Tregs). After 2 days, Tregs were re-sorted and tested in readout assays. Data points show the means for pooled values from 3 independent experiments. (C) Tregs were activated in cocultures as described above, and APCs were either TDLN pDCs, non-pDC fraction from the same TDLN (CD11c+B220–), pDCs from mice without tumors, or TDLN pDCs from IDO-KO mice. Graphs show 1 representative of 3–4 similar experiments for each group (bars show SD of replicate wells). (D) Tregs were activated with TDLN pDCs as described above, with or without 1MT. Tregs were re-sorted and added to readout assays in the lower chamber of transwell plates; upper chambers received readout assays without Tregs. Thymidine incorporation was measured separately in each chamber. One of 3 experiments; *P < 0.01 by ANOVA. (E) IDO-activated Tregs were sorted and added to readout assays containing A1 T cells plus either CBA DCs or CBA B cells. One of 3 experiments; *P < 0.01 by ANOVA.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts